GILD · News · 20261030N

Veklury Sales Decline

GILEAD SCIENCES, INC. · 2026-10-30 · Importance 45 · Surprise 64

Veklury sales fell 69% year over year to $86 million in the third quarter of 2026. The report attributed the decline to lower COVID-19 hospitalizations, indicating weaker demand for the COVID-19 treatment. The reported sales change exceeds the 10% threshold for inclusion.

Key facts